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PURPOSE.Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
is a progressive disease with no treatment option. Previous studies show chemokine-
mediated recruitment of immune cells in the retina, and therefore we investigated
systemic levels of chemokines and chemokine receptors in patients with GA.
METHODS. This observational prospective study was conducted at a single center. We
included 122 participants with no immune disease: 41 participants with GA and
no choroidal neovascularization, 51 patients with neovascular AMD, and 30 healthy
control individuals. Flow cytometric analysis was used to detect expression level of C-
C chemokine receptor (CCR)1, CCR2, CCR3, CCR5, and C-X-C motif chemokine receptor
(CXCR)3 on peripheral blood mononuclear cells (CD14+ monocytes, CD4+ T cells, CD8+
T cells). Plasma levels of C-C motif ligand (CCL)11, C-X-C motif chemokine (CXCL)10,
and CCL5 were measured by specific immunoassays. Enlargement rate of GA lesion was
measured from autofluorescence images.
RESULTS. Participants with GA have a specific chemokine profile with a higher expression
of CCR5 than healthy controls in peripheral blood mononuclear cells, and a higher plasma
levels of CCL-5. Further, GA was associated with higher monocytic expression of CCR2
than in neovascular AMD. We found that a high expression level of CCR5 on CD8+ T
cells was associated with slower enlargement rate of atrophic lesion.
CONCLUSIONS. The study showed an association between systemic chemokine profile and
GA formation. Further studies are needed to fully elucidate the possible role of systemic
chemokine regulation in mediating pathogenesis of GA.
Keywords: age-related macular degeneration, geographic atrophy, neovascular AMD,
chemokine, chemokine receptor
Age-related macular degeneration (AMD) is a prevalentmultifactorial disease, characterized by degeneration
of the retinal tissue and progressive loss of visual func-
tion. Two late stages are described, which sometimes are
seen in conjunction. The neovascular late stage with forma-
tion of choroidal neovascularization (CNV), leading to leak-
ing and bleeding into the retinal layers, and resulting in
the formation of fibrovascular scar tissue. The atrophic late
stage, termed geographic atrophy (GA), is seen as extending
atrophic lesions involving the outer photoreceptor layer, reti-
nal pigment epithelium (RPE), and choriocapillaris. These
atrophic lesions often form parafoveally and expand grad-
ually to ultimately involve the fovea.1 Morphologically, the
two late stages of AMD are very distinct, and in this study, we
chose to include patients with GA only or CNV to compare
these subgroups from an etiological perspective.
The involvement of immune cells in the pathology of
AMD is widely accepted. Infiltrating immune cells have been
shown in donor retinas and choroids of AMD patients,2
and several studies have shown the pivotal involvement of
chemokines in this recruitment.3,4 Immune cell infiltration
holds a homeostatic role in the resolution of inflammation.
During inflammation, recruitment of phagocytic immune
cells can clear toxic extracellular material, and thereby
relieve tissue stress and preserve tissue function.5 However,
late stage AMD is characterized by the chronic presence
of subretinal immune cells in large drusen, in the advanc-
ing junctional zone of atrophic lesions, and in CNVs. Hence
these cells are highly suspective to play a central role in
disease progression.6 Therefore we included GA progres-
sion rate as a secondary outcome to explore any association
between chemokine expression on different cell types and
the individual loss of retinal tissue.
Cells of the innate immune system (monocytes,
macrophages, dendritic cells, and natural killer cells) and
the adaptive immune system (CD4+ T cells, CD8+ T cells,
and B cells) are characterized by the constant mobility
from the blood and lymphatic system into and within
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tissue. Chemokines and their receptors have key roles in
the movement of immune cells and are implicated in a
wide range of inflammatory diseases involving the central
nervous system.7 One chemokine can bind to several recep-
tors, and receptors are sensitive to several ligands.8 C-C
chemokine receptor (CCR)1 and CCR2 have been found to
be upregulated in CD14+ CD16+ monocytes in patients
with neovascular AMD.9 CCR2+ monocyte cells have been
shown to infiltrate the subretinal space in the atrophic
lesions in donor eyes with GA.4 Further, C-C motif ligand
(CCL)2-CCR2 interaction has been implicated in CNV forma-
tion.10 The C-X-C motif chemokine receptor (CXCR)3 has
important inhibitory functions in angiogenesis and has been
found to be expressed at lower levels on CD8+ T cells in
patients with neovascular AMD.11 Further, its ligand, C-X-
C motif chemokine (CXCL)10, is found increased in aque-
ous humor from patients with AMD.12 CCR3 is expressed in
choroidal neovascular cells, in which signaling with ligand
CCL11 leads to proliferation and CNV growth. Blocking of
this signaling has been suggested as a treatment target in
neovascular AMD.13 CCL5, also known as RANTES (regu-
lated on activation, normal T cell expressed and secreted),
is a chemotactic cytokine that regulates inflammatory cell
migration, is suggested to influence the course of AMD
through secretion by RPE cells.14 CCL5 is implicated in other
age-related neurodegenerative diseases, such as Parkinson
disease.15
In this study, we aimed to map alterations in chemokine
levels and chemokine receptor expression on circulating
immune cells, CD14+ monocytes, CD4+ T cells, and CD8+
T cells from patients with GA, and to explore whether
chemokine receptor levels were associated with GA enlarge-
ment rate.
METHODS
Participants and Inclusion
This was a prospective case–control study. The study
adhered to the tenets stated in the Declaration of Helsinki
and was approved by the Regional Committee on Health
Research Ethics (journal no. SJ-385).
All patients were recruited from the retinal outpatient
program at Zealand University Hospital, Roskilde, Denmark.
Patient spouses participated as healthy controls to best
match patients in terms of age and lifestyle choices. All
participants had the nature of the study explained verbally
and written, and gave informed consent prior to participa-
tion.
Participants were subjected to a structured interview
regarding past medical history, medication use, tobacco
and alcohol use, and a single sentence question was used
to assess regular physical activity.16 Participants were not
included if they had any ongoing infectious or inflamma-
tory disorders, used any immune modulating medication,
or suffered from any cancer disease. Participants with C-
reactive protein (CRP) level above 15 mg/L were excluded
post hoc, due to suspected acute inflammation, as studies
have found that in healthy aged individuals, 15 mg/L repre-
sents the 99th percentile.17
Fresh blood sample was obtained at initial visit into one
vacutainer coated with ethylenediaminetetraacetic acid for
flow cytometry, and two vacutainers coated with lithium-
heparin for plasma isolation and for measurement of CRP.
Retinal Diagnosis
All participants, both patients with AMD and healthy
controls, underwent detailed ophthalmological examination
of both eyes, including best corrected visual acuity accord-
ing to the protocol Early Treatment Diabetic Retinopa-
thy Study,18 indirect dilated fundoscopy, digital fundus
photography, spectral domain optical coherence tomogra-
phy, and fundus autofluorescence image. All examinations
were performed by a retinal specialist. Retinal angiography
using fluorescein and indocyanine green was used only in
cases of suspected CNV to secure diagnosis of neovascular
AMD.
Eyes were graded according to the Clinical Age-Related
Maculopathy Grading System (CARMS),19 and patients
were included in the following categories:
• Healthy controls had no ocular disease, less than 10
small drusen (<63 μm), no pigment abnormalities,
equivalent to CARMS grade 1, in both eyes.
• Patients with GA had sharply demarcated areas of
atrophy in the macular area, involving the RPE and
outer photoreceptor layer in one or both eyes. Equiv-
alent to CARMS grade 4. Patients in this group did
not have any history or clinical signs of any former
CNV.
• Patients with neovascular AMD had nondrusenoid
pigment epithelial detachments, serous retinal
detachments, and choroidal neovascular membrane
with subretinal fluid, hemorrhages or fibrosis in one
or both eyes, equivalent to CARMS grade 5.
Chemokine Receptor Expression
We performed flow cytometric analysis on venous blood
samples within 4 hours of phlebotomy. White cell count
was determined using the automated hematology analyzer
system Sysmex KX-21N (Sysmex Corporation, Kobe, Japan)
to calculate the blood volume equivalent to a constant final
number of leukocytes in the test tube (5 ×·105 leukocytes).
Red blood cell lysis buffer (Nordic Biosite AB, Täby, Sweden)
was added, and the blood volume was lysed for 10 minutes
at room temperature in the dark. The cells were washed
three times using isotonic buffer solution (BD Biosciences,
Franklin Lakes, NJ, USA), the suspension was centrifuged for
5 minutes at 500g, decanted and resuspended. Samples were
aliquoted into two identical tubes. Fluorochrome-coupled
antibodies were added to one tube, and corresponding
isotype controls of each antibody was added to the second
tube (Supplementary Table S1). Both tubes were incubated
in the dark at room temperature, washed and resuspended
in isotonic buffer. Cells were analyzed within 4 hours of
phlebotomy using the BD FACSCanto II flow cytometer (BD
Biosciences) with a sample size of 100,000 singlet leuko-
cytes using a preset gate. Final analysis was performed using
Kaluza Software v. 1.5.20365.16139 (Beckman Coulter, Inc.,
Pasadena, CA, USA).
All cells were plotted on a forward scatter area versus
forward scatter height to select singlet cells. Monocytes and
lymphocytes were identified from their size and complex-
ity shown in a forward scatter area versus side scatter area.
Lymphocytes were divided into subsets according to their
expression of CD4 and CD8. Monocytes were gated by CD14
expression. Individual chemokine receptor expression was
determined for each cell type from fluorescence intensity of
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TABLE 1. Participant Characteristics
Diagnosis
GA, n = 41 Healthy Controls, n = 30 Neovascular AMD, n = 51 P Value
Age, y (SD) 78.4 (6.5) 75.6 (6.1) 75.8 (7.4) 0.129*
Sex, no. (%)
Female 26 (63) 15 (50) 26 (51) 0.430†
Male 15 (37) 15 (50) 25 (49)
Smoking, no. (%) 11 (27) 3 (10) 15 (29) 0.353†
Current
Previously 17 (42) 15 (50) 22 (43)
Never 13 (32) 12 (40) 14 (28)
Alcohol, median (IQR) 4.0 (2.0–8.0) 4.0 (2.0–7.0) 3.0 (0.5–8.5) 0.565‡
Body mass index, mean (SD) 26.7 (6.0) 25.7 (3.6) 26.1 (4.0) 0.706*
Exercise, no. (%) 26 (63) 18 (64) 27 (53) 0.480†
Hypertension, no. (%) 24 (59) 10 (33) 27 (53) 0.092†
Hypercholesterolemia, no. (%) 14 (34) 9 (30) 13 (26) 0.674†
Cardiovascular disease, no. (%) 15 (37) 4 (13) 12 (24) 0.076†
Type 2 diabetes, no. (%) 6 (15) 0 6 (12) 0.116†
CRP, mg/L
<2.9, no (%) 23 (56) 26 (87) 32 (63) 0.055§
3–10, no (%) 15 (37) 4 (13) 14 (27.5)
10–15, no (%) 3 (7) 0 5 (10)
IQR, interquartile range.
* One-way ANOVA.
† χ2 test.
‡ Kruskal-Wallis test.
§ Fisher’s Exact test.
each fluorochrome-specific antibody, with negative isotype
controls set at 1% threshold. Gating strategy is shown in
Supplementary Figure S2. Two investigators performed flow
cytometric analysis blinded from diagnosis or any clinical or
demographic information.
Plasma Chemokine Concentration
One lithium-heparin coated tube was centrifuged for 15
minutes at 1500g to eliminate cells. Plasma was immediately
pipetted, aliquoted, and stored at –80°C. Plasma levels of
CCL11, CXCL10, and CCL5 were measured using commer-
cially available multiplex immunoassays (Meso Scale Discov-
ery, Gaithersburg, MD, USA). Samples were diluted 50-fold,
plates were prepared according to manufacturer’s instruc-
tions, and reading was performed immediately on Quick-
Plex SQ120 (Meso Scale Discovery). Concentrations were
calculated from the eight-point standard curve in each plate.
All samples were run in duplicate and performed randomly
across plates, and investigators (MKN and YS) were blinded
from diagnosis. The coefficient of variance (CV) was calcu-
lated between each duplicate test, and tests were repeated if
the CV value exceeded 20%. The quality of each chemokine
assays was satisfactory (CV in % of mean ± SD: CCL11: 3.2
± 2.4; CXCL10: 3.3 ± 2.3; CCL5: 3.7 ± 3.3).
Enlargement Rate of Atrophic Lesion in GA
Patients with GA were invited for follow-up examination
after 1 year from inclusion. The procedures used for anal-
ysis and grading of autofluorescence images have been
published elsewhere.20
Data Analyses
All analyses were performed using the Statistical Package
for the Social Sciences (IBM Corporation, Armonk, NY,
USA). Normally distributed data are presented using mean
and standard deviation (SD), and compared using para-
metrical test. Not normally distributed data are presented
using median and interquartile range and compared using
nonparametrical tests. Categorical data are compared using
the χ2 test. Associations were described using univariate
linear regression. P values below 0.05 were interpreted as
statistically significant, and effect size was estimated after
calculation of Cohen’s d, interpreted as suggested by Cohen:
>0.2 small, >0.5 moderate, >0.8 large.21
RESULTS
Participants
A total of 127 participants were enrolled in the study. Five
individuals were excluded post hoc due to elevated levels
of CRP: one healthy control (CRP = 17 mg/L), one partic-
ipant with GA (CRP = 20 mg/L), and three participants
with neovascular AMD (CRP = 17, 18, and 70 mg/L). There-
fore 122 participants were included in the final analysis: 41
participants with GA, 30 healthy control individuals, and 51
participants with neovascular AMD.
Participants did not differ significantly in demographic
background, lifestyle, or comorbidities, as presented in
Table 1. Patients with any AMD had a tendency toward
higher occurrence of hypertension (P = 0.092), and cardio-
vascular disease (P = 0.076). This is in line with current liter-
ature, describing hypertension and cardiovascular disease
as associated with late-stage AMD.22 Similarly, there was
a tendency toward higher levels of CRP in patients with
AMD (P = 0.055), in particularly in patients with GA. These
changes demonstrate that the selected population is repre-
sentative as CRP, as well as other markers of chronic inflam-
mation is known to be elevated in late-stage AMD.20,23 The
patients with neovascular AMD had the disease for a median
period of 20.5 months (range, 1–92). All patients with
Downloaded from iovs.arvojournals.org on 06/15/2020
Chemokines in Geographic Atrophy IOVS | April 2020 | Vol. 61 | No. 4 | Article 28 | 4
TABLE 2. Chemokine Receptor Expression on Peripheral Blood Mononuclear Cells, Reported as Percentage of Positive Cells from the Given
Population. Chemokine Concentrations are Measured in Plasma. Measures are Reported as Median and Interquartile Range.
Diagnosis P Value*
GA, n = 41 HC, n = 30 nAMD, n = 51 GA vs. HC GA vs. nAMD HC vs. nAMD
CD14+ monocytes
CCR1 36.4 (29.8–51.8) 27.1 (1.8–55.8) 36.9 (19.0–62.5) 0.345 0.957 0.459
CCR2 93.7 (90.5–96.9) 92.2 (84.6–96.6) 91.9 (83.5–95.7) 0.068 0.042 0.969
CCR5 1.2 (0.9–1.9) 0.5 (0.2–1.3) 1.0 (0.5–1.6) <0.001 0.009 0.180
CXCR3 0.85 (0.6–1.9) 0.5 (0.3–0.9) 0.8 (0.5–1.5) 0.021 0.370 0.047
CD4+ T cells
CCR1 0.2 (0.1–7.7) 0.2 (0.1–0.7) 0.2 (0.1–0.3) 0.122 0.074 0.704
CCR2 6.1 (3.9–9.9) 5.5 (3.5–10.6) 5.8 (3.8–8.9) 0.618 0.749 0.799
CCR5 2.5 (1.3–4.6) 1.1 (0.7–3.6) 1.8 (1.0–3.6) 0.024 0.190 0.225
CXCR3 4.3 (1.1–11.4) 2.9 (0.8–6.9) 2.7 (1.8–4.5) 0.367 0.270 0.845
CD8+ T cells
CCR1 0.6 (0.2–2.6) 0.3 (0.1–1.0) 0.2 (0.2–0.9) 0.213 0.294 0.795
CCR2 6.8 (4.9–11.3) 7.2 (5.8–11.8) 8.1 (5.7–11.3) 0.906 0.576 0.681
CCR5 11.5 (6.1–16.3) 5.1 (2.8–12.2) 10.3 (4.2–17.0) 0.031 0.603 0.087
CXCR3 5.7 (1.1–16.2) 5.0 (1.0–11.2) 4.2 (1.8–8.5) 0.506 0.502 0.992
Plasma chemokine concentration
CCL11, pg/mL 951 (783–1161) 881 (741–1064) 988 (736–1239) 0.442 0.950 0.401
CXCL10, pg/mL 513 (393–732) 430 (330–560) 478 (308–585) 0.073 0.217 0.532
CCL5, pg/mL 42,115 (27,922–56,108) 29,528 (24,791–37,174) 27,568 (18,887–39,708) 0.017 0.001 0.484
HC, healthy control; nAMD, neovascular age-related macular degeneration.
Bold values indicate P-value ≤ 0.05.
* Mann-Whitney U test.
neovascular AMD received treatment with regularly admin-
istered intravitreal anti-vascular endothelial growth factor.
Criteria for retreatment was based on the Danish Ophthal-
mological Society guideline and recommendations.24
Chemokine Receptor Expression
Patients with GA had an increased proportion of CCR5+
peripheral blood mononuclear cells compared with healthy
controls. Monocytic expression of CCR5 was significantly
increased in patients with GA, with a small effect size (P
< 0.001, Cohen’s d = 0.3) and in patients with neovascular
AMD (P = 0.009, Cohen’s d = 0.2) compared with healthy
controls. Patients with GA also had a significantly higher
expression of CCR5 in CD8+ T cells, (P = 0.024, Cohen’s
d = 0.4) and in CD4+ T cells, in which the difference was
found to have a moderate effect size (P = 0.031, Cohen’s d
= 0.5). Expression of CCR5 on T cells did not differ between
patients with neovascular AMD and healthy controls.
Patients with GA had increased expression of CCR2 on
CD14+ monocytes compared with patients with neovascular
AMD (P = 0.042, Cohen’s d = 0.6), and to a lesser extent
compared with healthy controls (P = 0.068, Cohen’s d =
0.6).
Expression of CXCR3 was found to be increased on
CD14+ monocytes both in patients with GA (P = 0.021,
Cohen’s d = 0.4) and in patients with neovascular AMD,
although the effect size was small (P = 0.047, Cohen’s d =
0.1). Expression is given in Table 2 and distribution shown
in Supplementary Figure S3.
Plasma Chemokine Levels
Patients with GA had significantly higher plasma levels of
CCL5, both compared with healthy controls (P = 0.017)
and patients with neovascular AMD (P = 0.001). Effect size
of this difference showed a moderate size (Cohen’s d =
0.7). Plasma levels of CCL11 and CXCL10 did not differ
across groups, however, there was a tendency toward higher
CXCL10 among patients with GA (P = 0.073).
Association with GA Progression During One Year
Considering that chemokine-mediated recruitment of
peripheral immune cells are known to play a role in late
stage AMD, but their exact role remains unknown, we
chose to test if a possible association existed between
the altered levels of chemokine expression levels and
the progression rate of GA. All patients with GA were
invited for a follow-up visit 1 year later, and from the 41
participants, 32 patients completed follow-up examination
on average after 13 months from baseline (range, 12–18
months). Overall GA enlargement rate was median 1.64
mm2/year (interquartile range, 0.95–2.17). After correction
for baseline area (square root transformation), we plotted
each of the measured receptors, as shown in the Figure.
We found that the proportion of CCR5+ CD8+ T cells
associated with enlargement of GA lesion (R2 = 0.154, P =
0.018) in a univariate model, with high expression of CCR5
being indicative of slower progression (Slope = –0.22; 95%
confidence interval, −0.40 to −0.04).
DISCUSSION
This study presents a peripheral chemokine profile for
patients with GA. Our findings strongly suggest a novel role
for the chemokine/chemokine receptor axis CCL5/CCR5 in
GA. We found that patients with GA had increased expres-
sion of CCR5 on peripheral blood mononuclear cells. The
involvement of CCR5 in GA and AMD is not previously
described, but CCR5 is known to play a central role in other
age-related neurodegenerative diseases. Further, we find
increased monocytic expression of CCR2. This is in line with
current literature, describing CCR2-mediated recruitment
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FIGURE. Enlargement rate of GA during 1 year was square root transformed (SQRT) for baseline area and plotted against plasma levels of
CCL5, CCR5+ CD14+ monocytes, CCR2+ CD14+ monocytes, CXCR3+ CD14+ monocytes, CCR5+ CD4+ T cells, and CD8 CCR5+ T cells).
This revealed a moderate but significant association between progression rate and CCR5 expression on CD8+ T cells.
of blood-derived mononuclear phagocytes as a central part
of disease mechanism.6 CCL2 is increased in eyes with GA,
and specifically found in the vessels and in the outer retina
adjacent with the atrophic lesion. Further, CCR2+ monocytes
are recruited and accumulated in the subretinal in patients
with GA. In an animal model of AMD, CCL2 deficiency
protects from photoreceptor degeneration.4 This add to the
notion that the CCR2-mediated recruitment of mononuclear
phagocytes are contributing to the progressive loss of retinal
tissue in GA.
The proinflammatory chemokine CXCR3 has been shown
to possess angiostatic and antifibrotic properties via the
binding of its ligand CXCL10.25,26 Interestingly, we find
increased expression of CXCR3 on monocytes in both
patient groups, but the tendency toward higher CXCL10 (P
= 0.073) was only found in patients with GA, the late-stage
characterized by the complete absence of angiogenesis and
fibrosis.
The chemokine receptor CCR-5 is widely expressed at
the cell surface of antigen-presenting cells (APCs). Effector
T cells and NK-cells produce CCR-5 ligands on binding of
APCs to their targets. Production of these ligands attracts
more CCR-5+ effector cells to the site. CCR-5 is particularly
important in the biology of CD8+ T cells, as it controls their
priming and maturation.27 Naive T cells do not express CCR-
5, but this is upregulated on CD8+ T cells on their entry into
lymph nodes. Effector T cells are guided to sites of inflamma-
tion by a gradient of chemokines. Microglia, astrocytes, and
neurons are able to produce the CCR5 ligands, CCL3, CCL4,
and CCL5, participating in a multistep adhesion cascade by
triggering CCR5 and activating cell surface integrins, promot-
ing transendothelial migration of circulating CCR5+ effector
T cells. CCR5-CCL5 interaction has been shown to play a key
role in several neuroinflammatory diseases, such as multi-
ple sclerosis, Rasmussen encephalitis, and cerebral malaria,
in which CD8+ CCR5+ T cells infiltrate the brain, lead-
ing to neuronal destruction.28,29 However, the physiologi-
cal functions of CCR5 in the central nervous system are not
fully understood, as CCR5-CCL5 interaction has also been
shown to hold a neuroprotective role. Loss of dopaminer-
gic neurons has been reported in CCR5 deficient mice,30
and CCL5 promotes neuronal survival in proapoptotic condi-
tions,31 and protects against certain encephalitis virus.32,33
We find CCR5 expression on CD8+ T cells to be nega-
tively correlated with GA enlargement rate, indicating that in
this particular disease, CCR5-CCL5 interaction might hold a
neuroprotective role. When considering that GA is a disease
characterized by low-grade chronic inflammation,20 it seems
likely that the role of CCR5-CCL5 interaction differs from
the role seen in diseases, such as Rasmussen encephalitis
and cerebral malaria, characterized by an acute inflamma-
tory response.
We find an overall low expression of CCR5 on CD14+
monocytes, which is not surprising because CCR5 is
not expressed on circulating monocytes under homeo-
static conditions. However, CCR5 is expressed on mono-
cytes during inflammation, and CCR5+ monocytes play a
crucial role in orchestrating an appropriate sepsis immune
response.34 In this study, CCR5 expression on monocytes is
slightly increased in patients with late-stage AMD, which is
in line with the association between both late stages of AMD
and systemic low-grade chronic inflammation, with the high-
est levels in patients with GA.20,23
Plasma levels of CCL5 increases as a function of age and
“inflammaging,”35 therefore it is not surprising to find this
chemokine increased in aged individuals and in patients
with GA, whom we have previously found to have accel-
erated immunological aging and chronic inflammation.20
Rentzos et al.36 reports a similar increase in plasma CCL5
in patients with Parkinson disease. Interestingly, one study
developed an in vitro blood–brain-barrier using SV40
T-antigen immortalized human brain microvascular
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endothelial cells, which did not secrete CCL5 under homeo-
static conditions, but when stimulated with proinflammatory
cytokines there was a dose-dependent increase in CCL5
production by the cells, simultaneously with a marked
degraded barrier function.37,38 Ageing and the associated
chronic inflammation has also been shown to trigger CCL-5
and CCL-7 release by human retinal pigment epithelial
cells and choroidal fibroblasts,39 but whether this release is
protective or harmful is debated. In vitro, CCL5 was able to
suppress expression of inflammatory cytokines (IL-1β, IL-6,
and TNF-α) in microglia. This suppression was not seen
in CCR5-knockout mice, suggesting that CCR5-signaling
protects neurons by suppressing microglia toxicity.40 This is
of particular interest, as inappropriate microglia activation
is another key feature in GA pathogenesis.41,42
Several limitations should be kept in mind when inter-
preting these results. The observational nature of this study
merely provides us with associations between events, such
as CCR5 expression and GA progression. However, a study
with a larger sample size is necessary to provide robust
data on the course of disease.43 Also, experimental studies
are needed to evaluate the causality of these events. The
two groups of late AMDs—GA and neovascular AMD—
obviously differ in terms of neovascularization, but they
also differ in the treatment with anti-vascular endothelial
growth factor. We are unaware if these antibodies might
influence the systemic levels of chemokines or chemokine
receptor expression in these patients. We did not include
treatment naive patients with neovascular AMD, as the
initial CNV-formation is associated with an acute immune
response.44 Further, we performed a small single-center
study, and larger studies are needed to perform multivariate
analysis, or to investigate the influence of GA subtypes on
chemokine profile.
CONCLUSIONS
AMD is an increasingly prevalent disease, which will
continue to affect visual health, daily functions, and quality
of life among thousands of elderly individuals. We find that
patients with GA have an altered chemokine profile, which
might be associated with disease progression. Chemokine
modulation might provide hope for a means against disease
development and progression of GA, which currently holds
no treatment option.
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